Advanced Filters
noise
Found 64,783 clinical trials
U Ulrika Gillespie, PhD

IMPACT-care (Improved Medication Communication and Patient Involvement at Care Transitions)

Background: Transitions of care, especially at hospital discharge, pose significant risks to patient safety. The World Health Organization (WHO) identifies this as a critical area for improvement, particularly for older patients who frequently experience preventable adverse drug events (ADEs) post-discharge.These risks often stem from poor communication between hospitals and subsequent …

65 years of age All Phase N/A
E Erik Rein-Hedin, MD

To Evaluate Dose and Safety of NanoEcho Particle-1 Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers and Rectal Cancer Patients.

Clinical nodal staging for rectal cancer tumours in early stages, is today shown to be unreliable and no precise or accurate methods exist. Thus, there is an unmet need for better clinical staging of rectal cancer in early stages. If new imaging techniques for clinical staging of early rectal cancer …

18 - 99 years of age All Phase 2
L Laura Monico, PhD

Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings

Our primary objective is to evaluate the ability of Boulder Care's telehealth-platform to create the necessary paradigmatic shift in Opioid Use Disorder (OUD) treatment to reach vulnerable populations, with targets that support both equitable and culturally-specific OUD treatment as well as business profitability.

18 years of age All Phase 1
D Diogo Almeida, MD

Study to Investigate the Efficacy, Safety, and Tolerability of FBL-MTX in Patients With Rheumatoid Arthritis

The goal of this clinical trial is to evaluate the efficacy of FBL-MTX administered by subcutaneous route in Rheumatoid Arthritis patients. Participants will be screened within 28 days prior to treatment period, to confirm that they meet the selection criteria for the study. Treatment period: The treatment period will consist …

18 years of age All Phase 2

Study of CM313 in Healthy Subjects

This study is a single center, randomized, open/double-blind, placebo-controlled, single dose, dose escalation Phase I clinical study aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacokinetic characteristics, and immunogenicity of CM313 administered subcutaneously or intravenously at different doses in healthy male subjects.

18 - 50 years of age Male Phase 1
C Charlotte Lemech

AMT-676 in Patients With Advanced Solid Tumors

This is a first-in-human, non-randomized, open-label, multicenter Phase 1 study will evaluate the Maximum tolerated dose (MTD)/the recommended Phase 2 Dose (RP2D), safety, tolerability, anti-drug activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-676 in Patients with Advanced Solid Tumors.

18 years of age All Phase N/A
M ModeX Therapeutics

Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2004 in patients with advanced tumors.

18 years of age All Phase 1/2
C Christine K Santa Ana, BS

Virtual Reality During Pediatric Cast Removal

This study is a randomized control trial of Virtual Reality during cast removal procedures at a pediatric tertiary care center.

4 - 12 years of age All Phase N/A
B Boehringer Ingelheim

A Study to Test Whether BI 1356225 Improves Impulsive Behavior in Men With Opioid Use Disorder Who Are Taking Buprenorphine

This study is open to men between 18 and 65 years of age with opioid use disorder. Opioid use disorder is also called opioid addiction or opioid dependence. People can join the study if they currently take a medicine called buprenorphine. People with opioid dependence can act on impulse, which …

18 - 65 years of age Male Phase 1
L Léa BRUNEAU, MD

Evaluation of the Effectiveness of Breathing Control Technique on Long COVID Symptoms at the Reunion University Hospital

Despite the controversy, on October 6, 2021, the World Health Organization (WHO) recognized Long Coronavirus disease (COVID) by officially defining it: " symptoms appeared 3 months after the onset of the primary infection by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), persisting for at least 2 months and which cannot …

18 years of age All Phase N/A

Simplify language using AI